Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk

被引：16
|
作者：
La Vecchia, Carlo [1 ,2 ]
机构：
[1] Univ Milan, Ist Ric Farmacol Mario Negri Milano, Dipartimento Med Lavoro, Milan, Italy
[2] Int Prevent Res Inst, Lyon, France
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2011年 / 60卷 / 10期
关键词：
BREAST-CANCER; METFORMIN; CONSENSUS; GLUCOSE;
D O I：
10.1016/j.metabol.2011.03.011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1357 / 1358
页数：2
相关论文
共 50 条
  • [31] Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus
    Singh, Samar
    Bhat, Jyoti
    Wang, Ping H.
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (01)
  • [32] Pharmacotherapy of type 2 diabetes mellitus
    Rendell, MS
    Kirchain, WR
    ANNALS OF PHARMACOTHERAPY, 2000, 34 (7-8) : 878 - 895
  • [33] Aldosterone and type 2 diabetes mellitus
    Zavatta, Guido
    Casadio, Elena
    Rinaldi, Eleonora
    Pagotto, Uberto
    Pasquali, Renato
    Vicennati, Valentina
    HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2016, 26 (01) : 53 - 59
  • [34] The prevention of type 2 diabetes mellitus
    Davies, MJ
    CLINICAL MEDICINE, 2003, 3 (05) : 470 - 474
  • [35] Type 2 diabetes mellitus risk and exercise: is resistin involved?
    Cobbold, Christian
    JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS, 2019, 59 (02) : 290 - 297
  • [36] Linagliptin In Type 2 Diabetes Mellitus
    Scott, Lesley J.
    DRUGS, 2011, 71 (05) : 611 - 624
  • [37] Screening for Type 2 Diabetes Mellitus
    Barkoudah, Ebrahim
    Weinrauch, Larry A.
    ANNALS OF INTERNAL MEDICINE, 2015, 163 (09) : 726 - 726
  • [38] Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
    Dabrowski, Mariusz
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (04) : 1 - 18
  • [39] Diabetes mellitus, hyperglycaemia and cancer
    Simon, D.
    Balkau, B.
    DIABETES & METABOLISM, 2010, 36 (03) : 182 - 191
  • [40] LinagliptinIn Type 2 Diabetes Mellitus
    Lesley J. Scott
    Drugs, 2011, 71 : 611 - 624
12345